Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
We believe in partnerships! That is why we are teaming up with Harvard in order to discover which bacteria influence the immune system. Find out more here: #UCB90 #DrivenByScience #Partnership https://t.co/Yk8yzdpeD0
— UCB News (@ucb_news) 16.07.2018 -
UCB subscribes to various initiatives as outlined in the @UN’s seventeen Sustainable Development Goals. Read what we do for each of the UN #SDGs here. #UCB90 https://t.co/B9cvM5RGrE
— UCB News (@ucb_news) 13.07.2018 -
Media: •UCB & Amgen resubmit BLA for potential new treatment of osteoporosis in postmenopausal women to the @US_FDA https://t.co/TFmGzsBMKZ https://t.co/V44Ger8iNk
— UCB News (@ucb_news) 13.07.2018
Highlights
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
